PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Prenen H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009